Roquefort Therapeutics’ (COIL) “House Stock” Rating Reiterated at Shore Capital Group

Shore Capital Group reissued their house stock rating on shares of Roquefort Therapeutics (LON:COIL) in a research report sent to investors on Monday, MarketBeat.com reports.

Roquefort Therapeutics Stock Performance

Roquefort Therapeutics stock opened at GBX 8 on Monday. Roquefort Therapeutics has a 12-month low of GBX 6.75 and a 12-month high of GBX 12.50. The stock has a 50-day simple moving average of GBX 9.08 and a 200 day simple moving average of GBX 9.37. The company has a quick ratio of 3.07, a current ratio of 0.63 and a debt-to-equity ratio of 8.18. The stock has a market capitalization of £34.14 million, a price-to-earnings ratio of -0.37 and a beta of 0.05.

About Roquefort Therapeutics

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.